Logo
x

Search

Subscribe Now

obstructive hypertrophic cardiomyopathy

BMS Presents Results of Mavacamten in P-III Study for Obstructive Hypertrophic Cardiomyopathy at ACC 2021

BMS Presents Results of Mavacamten in P-III Study for Obstructive Hypertrophic Cardiomyopathy at ACC 2021

  • May 17, 2021
BMS Presents Clinical and RWE Data of Mavacamten for Obstructive Hypertrophic Cardiomyopathy at ACC 2021

BMS Presents Clinical and RWE Data of Mavacamten for Obstructive Hypertrophic Cardiomyopathy at ACC 2021

  • May 4, 2021
BMS Reports the US FDA's Acceptance of NDA for Mavacamten to Treat Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)

BMS Reports the US FDA's Acceptance of NDA for Mavacamten to Treat Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)

  • March 22, 2021
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.